Samsung Bioepis has unveiled Phase III interim analysis data for SB15, a proposed biosimilar for Eylea (aflibercept), in a paper presented before the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held between 30 September and 3 October.
Samsung Bioepis Presents Phase III Data For Eylea Biosimilar
Company Also Releases New Immunogenicity Results On Byooviz Ranibizumab Biosimilar
Samsung Bioepis presented three new studies on two of its blockbuster biosimilars at the American Academy of Ophthalmology 2022 Annual Meeting, including Phase III data for its proposed aflibercept rival to Eylea.
More from Products
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
More from Generics Bulletin
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.